Idiopathic Pulmonary Fibrosis Market: Advancing Therapies and Changing Treatment Dynamics

Idiopathic Pulmonary Fibrosis Market Overview

Idiopathic pulmonary fibrosis (IPF) is a progressive and chronic interstitial lung disorder marked by persistent scarring of the lung tissue. As fibrosis advances, lung function gradually declines, resulting in increasing respiratory difficulties and reduced quality of life. The idiopathic pulmonary fibrosis treatment market is undergoing significant transformation as established antifibrotic therapies continue to play an important role while innovative treatments are being developed to address limitations associated with existing approaches. DelveInsight's analysis evaluates the IPF landscape across the 7MM, comprising the United States, EU4, the United Kingdom, and Japan, with market projections extending through 2036.

Idiopathic Pulmonary Fibrosis Disease Burden and Epidemiology

IPF predominantly affects older adults and is associated with gradual deterioration in pulmonary function. According to DelveInsight's epidemiological assessment, the 7MM had approximately 300,000 diagnosed prevalent cases in 2025. The United States accounted for the largest proportion, with nearly 125,000 diagnosed prevalent cases during the same year. Within Europe, the United Kingdom had approximately 37,500 cases, while France recorded around 12,300 cases.

Several factors may influence the observed and future disease burden, including population aging, improvements in awareness, advances in diagnostic techniques, and greater recognition of patients presenting with respiratory symptoms. The growing prevalence of comorbid conditions may further complicate disease management and increase healthcare requirements.

Age remains an important demographic factor in the epidemiology of IPF. DelveInsight's epidemiological analysis identified individuals aged 60–79 years as the largest affected age group, followed by those aged 80 years and above. Diagnosed prevalent cases have also historically been higher among males than females across the 7MM. These demographic trends are relevant to diagnosis, treatment utilization, healthcare planning, and future commercial opportunities within the idiopathic pulmonary fibrosis market.

Idiopathic Pulmonary Fibrosis Current Treatment Landscape

The primary objectives of IPF management include slowing the decline in lung function, controlling symptoms, managing complications, and maintaining patients' overall functional status. Nintedanib and pirfenidone have traditionally represented the core pharmacological options for slowing disease progression. However, these treatments do not reverse established fibrosis, and tolerability concerns, including gastrointestinal adverse events, may affect treatment continuation for some patients.

The therapeutic environment has recently gained an additional option with the introduction of JASCAYD (nerandomilast). DelveInsight reports that the U.S. Food and Drug Administration approved JASCAYD in October 2025, making it the first newly approved IPF therapy in more than a decade. Its arrival demonstrates the increasing emphasis on developing therapies capable of addressing biological mechanisms beyond the established antifibrotic treatment paradigm.

Idiopathic Pulmonary Fibrosis United States Market Dynamics

The United States continues to represent a major market for IPF therapies due to its sizeable diagnosed patient population, advanced healthcare infrastructure, established diagnostic capabilities, and availability of innovative treatment options. The us idiopathic pulmonary fibrosis treatment market is expected to remain an important contributor to the overall 7MM market during the forecast period.

Improved recognition of IPF and advances in diagnostic assessment may support earlier identification of affected individuals. Diagnostic evaluation can include pulmonary function testing, high-resolution computed tomography, laboratory investigations designed to exclude alternative causes of interstitial lung disease, and, where clinically appropriate, lung biopsy. More accurate diagnosis can help physicians initiate disease management at an earlier stage.

Market development in the United States will also depend on factors such as reimbursement conditions, pricing considerations, regulatory decisions, physician adoption, and the availability of novel therapies. These factors can influence patient access as well as the commercial uptake of both established and emerging treatments.

Idiopathic Pulmonary Fibrosis European Market Outlook

European countries represent an important part of the global IPF treatment landscape, with the EU4 countries and the United Kingdom contributing substantially to overall market revenues. The europe idiopathic pulmonary fibrosis treatment market encompasses Germany, France, Italy, Spain, and the United Kingdom. DelveInsight estimates that the combined market size across the EU4 and UK approached USD 702 million in 2023, accounting for approximately 21% of the total 7MM market.

Germany represented approximately USD 183 million of the market in 2023, followed by the United Kingdom at around USD 141 million and France at nearly USD 140 million. Differences in healthcare infrastructure, reimbursement mechanisms, treatment guidelines, physician preferences, and patient access contribute to variations in treatment adoption across individual European markets.

Disease severity can also affect treatment utilization. As healthcare systems continue to improve recognition and management of IPF, opportunities may emerge for increasing diagnosis and treatment rates. At the same time, health technology assessments, pricing negotiations, and reimbursement frameworks will remain important factors influencing the commercialization of innovative therapies throughout Europe.

Idiopathic Pulmonary Fibrosis Emerging Therapies and Pipeline Development

Future developments in IPF are increasingly focused on therapies designed to target diverse biological mechanisms associated with fibrosis and progressive lung damage. The expanding pipeline reflects continuing efforts to address unmet needs related to disease progression, treatment tolerability, and the limitations of current therapeutic options.

According to DelveInsight, several candidates have attracted attention within the developing treatment landscape, including pamrevlumab, inhaled treprostinil, PLN-74809, BI 1015550, C21, and BMS-986278. Deupirfenidone (LYT-100) has also remained an area of development interest. PureTech reported a successful End-of-Phase II meeting with the FDA in December 2025 and outlined plans for the Phase III SURPASS-IPF study.

The broader fibrotic diseases treatment market is also benefiting from growing research into pathways associated with inflammation, extracellular matrix remodeling, fibrotic signaling, and progressive tissue injury. Continued investigation of these mechanisms could expand the range of therapeutic strategies available for patients with progressive fibrotic lung diseases.

Idiopathic Pulmonary Fibrosis Competitive Landscape and Future Growth

The competitive environment includes established pharmaceutical organizations and biotechnology companies working on therapies with different mechanisms of action. DelveInsight highlights companies such as FibroGen, United Therapeutics, Pliant Therapeutics, Boehringer Ingelheim, Vicore Pharma, and Bristol Myers Squibb among participants involved in the evolving IPF landscape.

Clinical trial outcomes, regulatory milestones, strategic collaborations, product launches, and investment in respiratory research are expected to influence competitive dynamics through 2036. The emergence of therapies with differentiated mechanisms may further reshape treatment algorithms and create additional opportunities within the market.

The evolving idiopathic interstitial pneumonias market also reflects advances in disease classification, biomarker research, imaging technologies, and clinical investigation. Research presented at the American Thoracic Society 2024 conference included developments involving biomarkers, differentiation between fibrotic hypersensitivity pneumonitis and IPF, circulating proteomic assessments, and approaches designed to improve prediction of disease type and severity.

Conclusion

The Idiopathic Pulmonary Fibrosis market is continuing to evolve as research efforts expand beyond conventional antifibrotic approaches and focus on new biological targets. Increasing disease recognition, demographic changes, advances in diagnostics, and the development of novel therapies are expected to influence treatment patterns and commercial opportunities over the coming years. Differences in healthcare systems, reimbursement structures, treatment access, and regulatory environments will also shape regional market development. Continued clinical research and innovation are likely to remain central to addressing the substantial unmet needs associated with this progressive respiratory disorder.

Latest Reports by DelveInsight:

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact

Company Name: DelveInsight Business Research LLP

Contact Person: Abhishek kumar

Email: abhishek@delveinsight.com

City: Albany

State: New York

Country: United States

Website: https://www.delveinsight.com

Share: